Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 2/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3936217 | 0.91 | MEN1 (0.47) | MEN1KMT2APBRM1NPC1MITF | |
| SCHEMBL22502136 | 0.88 | L3MBTL1 (0.50) | MEN1KMT2APBRM1NPC1MITF | |
| SCHEMBL18175996 | 0.84 | MEN1 (0.47) | MEN1KMT2APBRM1NPC1MITF | |
| SCHEMBL12491389 | 0.84 | ATR (0.44) | MEN1KMT2APBRM1NPC1MITF | |
| SCHEMBL4661424 | 0.82 | CDK4 (0.54) | MEN1KMT2APOLBALDH1A1HDAC6 | |
| SCHEMBL4488661 | 0.81 | PHLPP2 (0.53) | LMNAALDH1A1HDAC6HTR1A | |
| SCHEMBL6346088 | 0.81 | ATR (0.51) | MEN1KMT2APBRM1NPC1MITF | |
| SCHEMBL4505325 | 0.80 | HDAC6 (0.50) | MEN1KMT2AHDAC6CDK4CCND1 | |
| SCHEMBL27572328 | 0.78 | MEN1 (0.42) | MEN1KMT2APBRM1NPC1MITF | |
| SCHEMBL12087009 | 0.78 | MEN1 (0.47) | MEN1KMT2APBRM1NPC1MITF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514468-B2 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-07 | — | — | US | disclosed |
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-08-31 | — | — | US | disclosed |
| EP-1527046-A1 | INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-05-04 | — | — | EP | disclosed |
| US-6858641-B2 | Substituted indolinones | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-02-22 | — | — | US | disclosed |
| WO-2004009546-A1 | INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-01-29 | — | — | WO | disclosed |
| EP-1379501-A1 | INDOLINONES, SUBSTITUTED IN POSITION 6, AND THEIR USE AS KINASE INHIBITORS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-01-14 | — | — | EP | disclosed |
| US-20030092756-A1 | Substituted indolinones | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-05-15 | — | — | US | disclosed |
| WO-2002081445-A1 | INDOLINONES, SUBSTITUTED IN POSITION 6, AND THEIR USE AS KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092756-A1 | Substituted indolinones | CDK1, CDK2, CDKL1 | MEN1 2916/4885KMT2A 2176/4885PBRM1 1424/4885 |
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | KDR, FLT1, EGFR | MEN1 1288/4885KMT2A 3530/4885PBRM1 817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.